Stricken language would be deleted from and underlined language would be added to present law. Act 536 of the Regular Session

1	State of Arkansas	As Engrossed: S3/13/13 A Bill		
2	89th General Assembly	A BIII		
3	Regular Session, 2013		SENATE BILL 965	
4				
5	By: Senator J. Dismang			
6				
7	For An Act To Be Entitled			
8	AN ACT TO AMEND UNCODIFIED SECTION 1 OF ACT 274 OF			
9	2013 TO EXCLUDE CERTAIN DRUGS FROM THE DEFINITION OF			
10	THERAPEUTIC CLASS; AND FOR OTHER PURPOSES.			
11				
12				
13		Subtitle		
14	TO AMEND UNCODIFIED SECTION 1 OF ACT 274			
15	OF 2013 TO EXCLUDE CERTAIN DRUGS FROM THE			
16	DEF	INITION OF THERAPEUTIC CLASS.		
17				
18				
19	BE IT ENACTED BY THE	GENERAL ASSEMBLY OF THE STATE (OF ARKANSAS:	
20	anamian i u	11.5. 1.6. 1.6.1.6.1.	5 0010 1 1 1 1	
21	SECTION 1. Uncodified Section 1 of Act 274 of 2013 is amended to read			
22	as follows:			
23	SECTION 1. Arkansas Code § 17-92-101(17), concerning the definition of			
24	_	pharmacy act, is amended to rea		
25	(17)(A)	-		
26	usually written as a formula by a physician, optometrist, dentist,			
27	veterinarian, or other licensed medicinal practitioner. It contains the			
28	names and quantities of the desired substance, with instructions to the			
29	pharmacist for its preparation and to the patient for the use of the medicine			
30	at a particular time and may authorize the pharmacist to substitute a			
31	therapeutically equivalent drug that is at a lower cost to the patient and			
32	communicate that authorization by any generally accepted means of			
33	communication of a prescription from a prescriber to a pharmacist.			
34		(B) A substitution of a therapeutically equivalent drug		
35 36	shall occur only after the prescriber grants such authorization for each			
20	DIESCITULIONA			

1	$\frac{(b)(1)}{(C)(1)}$ before dispensing, the pharmacist shall		
2	discuss verbally any suggested substitution with the patient and inform the		
3	patient that the patient has a right to refuse the substitution.		
4	(ii) The discussion under subdivision $\frac{(17)(B)(i)}{(11)}$		
5	(17)(C)(i) of this section shall include without limitation:		
6	(a) Notification to the patient that the		
7	therapeutically equivalent drug does not contain the identical active		
8	ingredient present in the prescribe prescribed drug; and		
9	(b) All differences in dosage and frequency		
10	between the prescribed drug and the therapeutically equivalent drug.		
11	$\frac{(G)}{(D)}$ The pharmacist shall send notice of the		
12	substitution to the prescriber in writing or by electronic communication		
13	within twenty-four (24) hours after the drug is dispensed to the patient.		
14	(E) Subdivision $(17)(B)$ of this section does not apply to		
15	specific acts of drug therapy management or disease state management		
16	delegated to a pharmacist based upon a written protocol or patient care plan		
17	approved by a physician under § 17-92-101(16)(A)(ix);		
18			
19	/s/J. Dismang		
20			
21			
22	APPROVED: 03/28/2013		
23			
24			
25			
26			
27			
28			
29			
30			
31			
32			
33			
34			
35			
36			